Join Canadian Insider Club or Club Ultra to Keep Your Edge
Times are changing, ad revenues are plunging, and Canadian data costs have jumped.
Starting this summer, we will be limiting Canadian company page views to 10 per month for non-members.
Canadian Insider Club members will continue to get Google ad-free and unlimited access to canadianinsider.com.
Join the club to keep your edge! For a limited time, use coupon code SAVE99 to save $99* off a Canadian Insider Club Membership.
*Save $99 on the first year of a new Canadian Insider Club or Canadian Insider Club Ultra membership. Subsequent auto-renewals will be at the standard rate unless canceled. Limited time offer.
Aequus Pharmaceuticals Inc. (V:AQS)
Business Focus: Pharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEDAR | |
| Company Contact | |
| Address: | 2820 Granville St VANCOUVER BC V6C 1S4 |
| Tel: | N/A |
| Website: | www.aequuspharma.ca |
| IR: | See website |
| Key People | ||
| Douglas Glen Janzen Chairman of the Board, President, Chief Executive Officer | Ann Fehr Chief Financial Officer | Anne Michelle Stevens Vice President - Corporate Development, Executive Director, Secretary |
| Business Overview |
| Aequus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products. The Company operates through the segment of sales and marketing of pharmaceutical drugs developed by the Company or by its collaborative partners. Its products include tacrolimus immediate releaser, which is an immunosuppressive therapy used for the treatment and prevention of acute rejection following organ transplantation; Vistitan, which is a ophthalmology product; Topiramate extended-release (XR), which is a once-daily topiramate product designed for patient compliance, and Oxcarbazepine XR, which is a once-daily oxcarbazepine product. Its development-stage pipeline includes various products in neurology and psychiatry. Its lead development-stage product candidate is AQS-1301. In addition, the Company is developing a pipeline of other central nervous system product candidates. It has over two preclinical-stage programs and a clinical-stage program in development. |
| Financial Overview |
| For the three months ended 31 March 2020, Aequus Pharmaceuticals Inc revenues increased 76% to C$579K. Net loss decreased 44% to C$406K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General administration - Balancing value decrease of 25% to C$237K (expense), Sales and marketing - Balancing value decrease of 11% to C$332K (expense), Management, wages. |
| Employees: | 11 as of Dec 31, 2019 |
| Reporting Currency: | Canadian Dollars |
| Enterprise value: | $10.18M as of Mar 31, 2020 |
| Annual revenue (TTM): | $1.88M as of Mar 31, 2020 |
| EBITDA (TTM): | -$1.36M as of Mar 31, 2020 |
| Net annual income (TTM): | -$2.78M as of Mar 31, 2020 |
| Free cash flow (TTM): | -$1.82M as of Mar 31, 2020 |
| Net Debt Last Fiscal Year: | $1.96M as of Mar 31, 2020 |
| Shares outstanding: | 80,437,970 as of Mar 31, 2020 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Company fundamental and
price data sourced from © Thomson Reuters Limited. All rights reserved. Republication or redistribution of
Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent
of Thomson Reuters. Thomson Reuters is not liable for any errors or delays in Thomson Reuters content, or for
any actions taken in reliance on such content. 'Thomson Reuters' and the Thomson Reuters logo are trademarks of
Thomson Reuters and its affiliated companies. US Quotes data provided by IEX.
Interactive technical study charts by TradingView. Copyright © 2020 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.